Payment overview · 2025
General Payments
$1,585.89
83 reported records · 19 companies
Healthcare provider profile · identity verified
Claude Osula, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · JASPER, AL · NPI 1235137688
Verified facts
What the public records show
CMS Open Payments records show Claude Osula, M.D. received $1,585.89 in general payments during 2025 across 83 reported records.
Novo Nordisk Inc accounted for 17.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 27 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Kerendia, Mounjaro, Nurtec Odt, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 125 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 351 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 215 claims for Jardiance by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLIZET as an associated drug or biological on 63 records involving 47 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Nexlizet by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 118 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 215 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 102 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 286 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 275 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Nurtec Odt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $271.50 | 17.1% | 14 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $214.70 | 13.5% | 13 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $208.35 | 13.1% | 9 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $135.27 | 8.5% | 7 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $102.56 | 6.5% | 5 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $98.24 | 6.2% | 5 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $91.08 | 5.7% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $63.45 | 4.0% | 4 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $53.99 | 3.4% | 2 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $53.61 | 3.4% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $48.46 | 3.1% | 3 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $46.42 | 2.9% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $45.44 | 2.9% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $36.00 | 2.3% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $30.97 | 1.9% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $29.11 | 1.8% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $21.52 | 1.4% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $18.86 | 1.2% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $16.36 | 1.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,585.89 | 83 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $209.04 | 11 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $179.28 | 9 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $160.26 | 6 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $135.27 | 7 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $133.65 | 8 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $102.56 | 5 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $98.24 | 5 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $91.08 | 5 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $88.95 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $81.62 | 4 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $81.05 | 5 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $67.61 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $63.45 | 4 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $53.99 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $53.65 | 3 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $53.61 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $48.46 | 3 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $46.42 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $41.39 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $36.00 | 2 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $31.52 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $30.97 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $29.11 | 2 | 2025 |
Source payment records
|
|||||
| General - Pain Management Normalized: general pain management |
Device | Boston Scientific Corporation | $21.52 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $18.86 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $16.36 | 1 | 2025 |
Source payment records
|
|||||
| JASCAYD Normalized: jascayd |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $13.92 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 275 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 351 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 102 | exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 286 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 118 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
125 | 21 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
351 | 71 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
215 | 37 |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLIZET open payments reported associated product |
CMS Open Payments — General Payments 63 supporting records · 47 recipient NPIs · example record 1243951667 |
Nexlizet · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
118 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
215 | 37 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
102 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
53 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
286 | 49 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
275 | 67 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1259 | 319 |
| Amlodipine Besylate | Amlodipine Besylate | 860 | 233 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 829 | 101 |
| Levothyroxine Sodium | Levothyroxine Sodium | 771 | 139 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 652 | 178 |
| Metoprolol Succinate | Metoprolol Succinate | 614 | 156 |
| Potassium Chloride | Potassium Chloride | 609 | 165 |
| Famotidine | Famotidine | 578 | 153 |
| Pantoprazole Sodium | Pantoprazole Sodium | 552 | 157 |
| Furosemide | Furosemide | 524 | 160 |
| Tramadol Hcl | Tramadol Hcl | 470 | 78 |
| Ezetimibe | Ezetimibe | 448 | 118 |
| Lisinopril | Lisinopril | 444 | 119 |
| Gabapentin | Gabapentin | 426 | 101 |
| Losartan Potassium | Losartan Potassium | 381 | 108 |
| Omeprazole | Omeprazole | 380 | 95 |
| Tamsulosin Hcl | Tamsulosin Hcl | 380 | 109 |
| Farxiga | Dapagliflozin Propanediol | 351 | 71 |
| Metformin Hcl | Metformin Hcl | 322 | 85 |
| Tizanidine Hcl | Tizanidine Hcl | 302 | 79 |
| Finasteride | Finasteride | 297 | 79 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 293 | 78 |
| Ozempic | Semaglutide | 286 | 49 |
| Eliquis | Apixaban | 275 | 67 |
| Metformin Hcl Er | Metformin Hcl | 265 | 73 |
| Carvedilol | Carvedilol | 261 | 80 |
| Hydrochlorothiazide | Hydrochlorothiazide | 253 | 77 |
| Clonazepam | Clonazepam | 249 | 30 |
| Clopidogrel | Clopidogrel Bisulfate | 248 | 67 |
| Meloxicam | Meloxicam | 247 | 83 |
| Buspirone Hcl | Buspirone Hcl | 239 | 61 |
| Glimepiride | Glimepiride | 238 | 61 |
| Alendronate Sodium | Alendronate Sodium | 236 | 71 |
| Escitalopram Oxalate | Escitalopram Oxalate | 235 | 61 |
| Duloxetine Hcl | Duloxetine Hcl | 231 | 60 |
| Raloxifene Hcl | Raloxifene Hcl | 229 | 66 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 220 | 61 |
| Pravastatin Sodium | Pravastatin Sodium | 218 | 54 |
| Alprazolam | Alprazolam | 217 | 25 |
| Jardiance | Empagliflozin | 215 | 37 |
| Methylprednisolone | Methylprednisolone | 211 | 172 |
| Glipizide | Glipizide | 200 | 57 |
| Pioglitazone Hcl | Pioglitazone Hcl | 200 | 54 |
| Metoprolol Tartrate | Metoprolol Tartrate | 195 | 51 |
| Enalapril Maleate | Enalapril Maleate | 182 | 44 |
| Sertraline Hcl | Sertraline Hcl | 180 | 44 |
| Mirtazapine | Mirtazapine | 173 | 46 |
| Bupropion Xl | Bupropion Hcl | 172 | 49 |
| Baclofen | Baclofen | 169 | 62 |
| Simvastatin | Simvastatin | 165 | 42 |
| Allopurinol | Allopurinol | 163 | 39 |
| Quetiapine Fumarate | Quetiapine Fumarate | 155 | 43 |
| Spironolactone | Spironolactone | 154 | 53 |
| Celecoxib | Celecoxib | 152 | 43 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 148 | 44 |
| Donepezil Hcl | Donepezil Hcl | 141 | 37 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 141 | 39 |
| Trazodone Hcl | Trazodone Hcl | 139 | 34 |
| Xarelto | Rivaroxaban | 136 | 26 |
| Lorazepam | Lorazepam | 130 | 20 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 125 | 40 |
| Fluticasone Propionate | Fluticasone Propionate | 125 | 54 |
| Synthroid | Levothyroxine Sodium | 125 | 21 |
| Ramipril | Ramipril | 124 | 34 |
| Pregabalin | Pregabalin | 121 | 39 |
| Doxycycline Hyclate | Doxycycline Hyclate | 120 | 101 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 118 | 20 |
| Memantine Hcl | Memantine Hcl | 110 | 35 |
| Montelukast Sodium | Montelukast Sodium | 109 | 31 |
| Clonidine Hcl | Clonidine Hcl | 108 | 26 |
| Citalopram Hbr | Citalopram Hydrobromide | 106 | 26 |
| Mounjaro | Tirzepatide | 102 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 99 | 25 |
| Entresto | Sacubitril/Valsartan | 98 | 18 |
| Hydralazine Hcl | Hydralazine Hcl | 96 | 32 |
| Ropinirole Hcl | Ropinirole Hcl | 96 | 27 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 91 | 12 |
| Warfarin Sodium | Warfarin Sodium | 90 | 12 |
| Atenolol | Atenolol | 88 | 25 |
| Bumetanide | Bumetanide | 88 | 23 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 87 | 30 |
| Tresiba Flextouch U-100 | Insulin Degludec | 86 | 18 |
| Aripiprazole | Aripiprazole | 85 | 22 |
| Methocarbamol | Methocarbamol | 84 | 43 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 84 | 12 |
| Prednisone | Prednisone | 84 | 61 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 82 | 22 |
| Nabumetone | Nabumetone | 81 | 28 |
| Zolpidem Tartrate | Zolpidem Tartrate | 78 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 77 | 17 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 77 | 20 |
| Ondansetron Hcl | Ondansetron Hcl | 75 | 33 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 74 | 28 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 73 | 19 |
| Levofloxacin | Levofloxacin | 73 | 61 |
| Breo Ellipta | Fluticasone/Vilanterol | 70 | 11 |
| Topiramate | Topiramate | 65 | 13 |
| Estradiol | Estradiol | 62 | 17 |
| Fenofibrate | Fenofibrate Nanocrystallized | 60 | 15 |
| Ondansetron Odt | Ondansetron | 57 | 25 |
| Colchicine | Colchicine | 55 | 15 |
| Benazepril Hcl | Benazepril Hcl | 53 | 14 |
| Fluconazole | Fluconazole | 53 | 42 |
| Trulicity | Dulaglutide | 53 | 11 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 46 | suppressed |
| Glipizide Er | Glipizide | 46 | 13 |
| Betamethasone Valerate | Betamethasone Valerate | 45 | 30 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 44 | 14 |
| Mupirocin | Mupirocin | 42 | 25 |
| Azithromycin | Azithromycin | 41 | 36 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 41 | 39 |
| Amitriptyline Hcl | Amitriptyline Hcl | 38 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 38 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 38 | 18 |
| Ipratropium Bromide | Ipratropium Bromide | 37 | suppressed |
| Verapamil Er | Verapamil Hcl | 37 | suppressed |
| Myrbetriq | Mirabegron | 36 | suppressed |
| Premarin | Estrogens, Conjugated | 36 | suppressed |
| Levetiracetam | Levetiracetam | 35 | 11 |
| Metoclopramide Hcl | Metoclopramide Hcl | 34 | 13 |
| Nortriptyline Hcl | Nortriptyline Hcl | 34 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 34 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 34 | 11 |
| Lansoprazole | Lansoprazole | 32 | suppressed |
| Lovastatin | Lovastatin | 31 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 30 | suppressed |
| Linzess | Linaclotide | 30 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 29 | 13 |
| Januvia | Sitagliptin Phosphate | 29 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 29 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 29 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 28 | 11 |
| Pen Needles | Pen Needle, Diabetic | 28 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 28 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 27 | suppressed |
| Gemfibrozil | Gemfibrozil | 27 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 27 | suppressed |
| Nitroglycerin | Nitroglycerin | 27 | 15 |
| Sildenafil Citrate | Sildenafil Citrate | 27 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 27 | 12 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 26 | suppressed |
| Rivastigmine | Rivastigmine | 26 | suppressed |
| Sucralfate | Sucralfate | 26 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 26 | 14 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 25 | 24 |
| Metronidazole | Metronidazole | 25 | 21 |
| Valacyclovir | Valacyclovir Hcl | 25 | suppressed |
| Levemir Flexpen | Insulin Detemir | 24 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 24 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 23 | 13 |
| Midodrine Hcl | Midodrine Hcl | 23 | suppressed |
| Naproxen | Naproxen | 23 | suppressed |
| Nystatin | Nystatin | 23 | 12 |
| Flecainide Acetate | Flecainide Acetate | 22 | suppressed |
| Minoxidil | Minoxidil | 22 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 22 | suppressed |
| Repatha Sureclick | Evolocumab | 22 | suppressed |
| Chlorthalidone | Chlorthalidone | 21 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 21 | 20 |
| Humalog Kwikpen U-200 | Insulin Lispro | 21 | suppressed |
| Multaq | Dronedarone Hcl | 21 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 21 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Valsartan | Valsartan | 21 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 20 | 11 |
| Prasugrel Hcl | Prasugrel Hcl | 20 | suppressed |
| Ranolazine Er | Ranolazine | 20 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 20 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 19 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 19 | suppressed |
| Primidone | Primidone | 19 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 19 | suppressed |
| Telmisartan | Telmisartan | 19 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 19 | suppressed |
| Dutasteride | Dutasteride | 18 | suppressed |
| Ibuprofen | Ibuprofen | 18 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 18 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 18 | suppressed |
| Testosterone | Testosterone | 18 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 17 | suppressed |
| Klor-Con M10 | Potassium Chloride | 17 | suppressed |
| Metolazone | Metolazone | 17 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 17 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 17 | suppressed |
| Enalapril-Hydrochlorothiazide | Enalapril/Hydrochlorothiazide | 16 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 16 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 16 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 14 |
| Cilostazol | Cilostazol | 15 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 15 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 15 | suppressed |
| Vascepa | Icosapent Ethyl | 15 | suppressed |
| Acyclovir | Acyclovir | 14 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 14 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | suppressed |
| Temazepam | Temazepam | 14 | suppressed |
| Verapamil Sr | Verapamil Hcl | 14 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 13 | suppressed |
| Carisoprodol | Carisoprodol | 13 | suppressed |
| Oxazepam | Oxazepam | 13 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 12 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 12 | 12 |
| Digoxin | Digoxin | 12 | suppressed |
| Estradiol (Twice Weekly) | Estradiol | 12 | suppressed |
| Kerendia | Finerenone | 12 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 12 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 12 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 11 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 11 | suppressed |
| Neupro | Rotigotine | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Sotalol | Sotalol Hcl | 11 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 11 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,585.89 · 83 records | Novo Nordisk Inc | ACCRUFER, AIRSUPRA, Auvelity, CAPLYTA, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, FARXIGA, General - Pain Management, JASCAYD, Kerendia, Korlym, MOUNJARO, NEXLETOL, NURTEC ODT, OFEV, Ozempic, QULIPTA, REPATHA, Rybelsus, TRELEGY ELLIPTA, UBRELVY, VERQUVO, VRAYLAR, Wegovy, XIFAXAN, ZAVZPRET | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error